Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Candel Therapeutics (CADL) stock rises as the company updates results from an ongoing mid-stage trial for its lead candidate, CAN-2409 in lung cancer. Read more here.

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revvity (RVTY – Research Report) and Candel Therapeutics (CADL – Research Repo ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Presenter: Mark G. Garzotto, M.D., Professor of Urology and Radiation Medicine, Oregon Health & Science University, Chief, Urology Section, Portland VA Medical Center Session Title: P2s: ...

EL PAÍS takes a journey through Ávila, Soria, Segovia and Valladolid in search of the places that captivated the brilliant ...